IMMUNIC (IMUX) BVF Partners (Director) Receives 25,370-Share Award

What Happened

• BVF Partners L.P. (reported as a director by deputization) acquired a derivative award of 25,370 shares in IMMUNIC, Inc. (IMUX) on 2026-09-16. The reported acquisition price is $0.00, resulting in a reported value of $0 at grant. Footnotes indicate the award is an option that vests in monthly increments over one year from the grant date.

Key Details

• Transaction date: 2026-09-16; Filing date: 2026-09-18 (filed within the typical 2-business-day Section 16 window).
• Consideration: $0.00 per share at grant (derivative award/option); total reported cash value at grant = $0.
• Vesting: Award vests monthly over one year (footnote F6).
• Shares owned after transaction: Not specified in the excerpted transaction details.
• Notable footnotes: joint filing by multiple BVF entities and individuals (F1); 1-for-10 reverse stock split effective 4/27/2026 affecting prior share counts (F2); complex ownership/pecuniary-interest disclosures and deputization arrangement involving R. Thorvald Nagel, BVF Inc., and Mark Lampert (F3–F7).
• Filing timeliness: Appears timely (filed two days after the transaction).

Context

• This was a derivative grant (award of options/rights), not a sale or open-market purchase. Such grants represent potential future ownership as the award vests and (if options) upon exercise — they are not immediate cash proceeds or sales.
• The reporting parties are institutional entities (BVF family of funds and affiliates) with disclosures indicating pecuniary interests and an agreement transferring economic benefit tied to a board member; treat this as institutional insider reporting rather than a direct executive personal trade.